Bausch Health Companies ( (BHC) ) has realeased its Q3 earnings. Here is a breakdown of the information Bausch Health Companies presented to its investors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Bausch Health Companies Inc., a diversified global pharmaceutical firm, focuses on delivering healthcare solutions across gastroenterology, neurology, dermatology, and eye health. In its latest earnings report for the third quarter of 2024, Bausch Health announced a continuation of its growth trend, marking its sixth consecutive quarter of year-over-year revenue and adjusted EBITDA growth. The company’s consolidated revenues reached $2.51 billion, a 12% increase from the previous year, with notable growth in all segments. However, the firm reported a GAAP net loss of $85 million, though this was a substantial improvement from the $378 million loss recorded in the same quarter last year. Its adjusted EBITDA rose by 10% to $909 million, reflecting strong operational performance despite higher administrative costs and interest expenses. The company also raised its full-year 2024 guidance, indicating confidence in its continued growth trajectory. Looking ahead, Bausch Health remains committed to advancing its R&D pipeline and strengthening its financial standing, reflecting a cautious yet optimistic outlook for the future.
